Physician profile
Matthew Block
NPI 1417997172
$1,247.85
in general payments reported to CMS, 2019-2025
17 companies · $255 in 2025
The $255 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.05 · 2021: $116 · 2022: $292 · 2023: $165 · 2024: $407 · 2025: $255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $827.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $826.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $162.30 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Boston Scientific Corporation | $143.30 | 2024-2025 | Watchman Flx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.27 | 2023-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $121.67 | 2022-2023 | Xarelto |
| Pfizer INC. | $119.81 | 2022-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $69.95 | 2022-2025 | Lifevest |
| Preventric Diagnostics, INC. | $69.68 | 2021 | |
| Esperion Therapeutics, INC. | $65.70 | 2025 | Nexletol |
| Novartis Pharmaceuticals Corporation | $64.46 | 2022-2023 | |
| Abbott Laboratories | $63.33 | 2024 | Jot Dx, Aveir |
| Irhythm Technologies, INC. | $61.64 | 2022-2024 | Zio Xt Patch, Zio Monitor |
| Lilly USA, LLC | $59.14 | 2022-2025 | Zepbound, Mounjaro |
| E.R. Squibb & Sons, L.L.C. | $51.51 | 2023-2025 | Camzyos, Eliquis |
| Daiichi Sankyo INC. | $18.46 | 2023 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $16.84 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $14.74 | 2025 | Verquvo |
| Amarin Pharma, INC. | $13.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Block listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.